Carbetocin 100mcg/1ml

Solution for injection

Indicated for the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia

Withdraw 1 ml of PABAL containing 100 micrograms carbetocin and administer only by intravenous injection, under adequate medical supervision in a hospital.

 Rocuronium bromide 50mg/5ml

Injection solution

Indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Posology
Like other neuromuscular blocking agents, Rocuronium-BFS should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these drugs.
As with other neuromuscular blocking agents, the dosage of Rocuronium-BFS should be individualised in each patient. The method of anaesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose.
The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery.
Inhalational anaesthetics do potentiate the neuromuscular blocking effects of Rocuronium-BFS. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with Rocuronium-BFS should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of Rocuronium-BFS during long lasting procedures (longer than 1 hour) under inhalational anaesthesia (see section 4.5).
In adult patients the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit.
 

Fondaparinux sodium 2.5 mg/0.5 ml

Solution for injection

Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery. 
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery 
Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease. 
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management (PCI) is not indicated 
Treatment of ST segment elevation myocardial infarction (STEMI) in adults who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy. 
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis

Fluconazole 2mg/ml

Soft Bag injection

Fluconazole is indicated in the following fungal infections
Fluconazole is indicated in adults for the treatment of:
▪ cryptococcal meningitis;
▪ coccidioidomycosis;
▪ invasive candidiasis;
▪ mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis;
▪ chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.
Fluconazole is indicated in adults for the prophylaxis of:
▪ relapse of cryptococcal meningitis in patients with high risk of recurrence;
▪ relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse;
▪ prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation).
Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:
▪ Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.
Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
Consideration should be given to official guidance on the appropriate use of antifungals.

Sodium chloride 0.9%

Solution for injection

For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
In the reconstitution, dilution and making up of certain drugs.
Use as a saline irrigant or as a priming fluid for haemodialysis procedures and to initiate and terminate blood transfusions.

Atosiban 7.5 mg/ml

Solution for injection

Atosiban is indicated to delay imminent pre-term birth in pregnant women with:
− regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes
− a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%
− a gestational age from 24 until 33 completed weeks
− a normal foetal heart rate

Treatment with Atosiban should be initiated and maintained by a physician experienced in the treatment of pre-term labour.

Atosiban is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Atosiban 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Atosiban 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Atosiban 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Atosiban therapy should preferably not exceed 330.75 mg of atosiban.

Intravenous therapy using the initial bolus injection should be started as soon as possible after diagnosis of pre-term labour. Once the bolus has been injected, proceed with the infusion (See Summary of Product Characteristics of Atosiban 37.5 mg/5 ml, concentrate for solution for infusion). In the case of persistence of uterine contractions during treatment with Atosiban, alternative therapy should be considered.

Carbazochrome sodium sulfonate 50mg/10ml

Solution for injection

Hemorrhagic tendency (purpura etc.) due to decreased capillary resistance and increased capillary permeability. 
Hemorrhage from skin, mucous membrane and internal membrane, hemorrhage at eyeground, nephrotic hemorrhage and metrorrhagia. 
Abnormal bleeding during and after operation due to decrease of capillary resistance.

Normal dose for adults is 25-100 mg daily, injection or infusion.
The dose should be up to the age and the severity of the disease.

Carbazochrome sodium sulfonate 25mg/5ml

Solution for injection

Hemorrhagic tendency (purpura etc.) due to decreased capillary resistance and increased capillary permeability. 
Hemorrhage from skin, mucous membrane and internal membrane, hemorrhage at eyeground, nephrotic hemorrhage and metrorrhagia. 
Abnormal bleeding during and after operation due to decrease of capillary resistance

Normal dose for adults is 25-100 mg daily, injection or infusion.
The dose should be up to the age and the severity of the disease.

Milrinone 10mg/10ml

Solution for injection

Indicated for the short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy, and for the treatment of patients with acute heart failure, including low output states following cardiac surgery. In paediatric population, indicated for the short-term treatment (up to 35 hours) of severe congestive heart failure unresponsive to conventional maintenance therapy (glycosides, diuretics, vasodilators and/or angiotensin converting enzyme (ACE) inhibitors), and for the short-term treatment (up to 35 hours) of paediatric patients with acute heart failure, including low output states following cardiac surgery.

Acetylcystein 200 mg/ml

N-acetylcysteine is indicated for the treatment of paracetamol overdose in patients:

a) who have taken a staggered overdose irrespective of plasma paracetamol level. Staggered is defined as an overdose where the paracetamol was ingested over a period of 1 hour or more; or

b) where there is any doubt over the time of the overdose, irrespective of plasma paracetamol level; or

c) who present with a plasma paracetamol level on or above a line joining points of 100mg/L at 4h and 15mg/L at 15h (see below nomogram).

Sodium bicarbonate: 840mg/10ml

Solution for injection

BFS-Nabica 8.4% is indicated in patients with severe acidosis (blood pH <7.0) for raising the pH to 7.1 in the following cases:
-    Cardiac arrest in patients with metabolic acidosis
-    Cardiac arrest due to hyperkalemia in patients with metabolic acidosis
-    Life-threatening due to hyperkalemia in people with metabolic acidosis
-    Over-use of tricyclic antidepressants.

Only administered intravenously at the following rates:
- 8.4% sodium bicarbonate injection solution: about 20-40 drops/min = 60-120 ml/hour.
Note: When infusing children with 8.4% sodium bicarbonate solution, dilute with distilled water in the ratio of 1: 1. In infants and children under 2 years of age, hypertonic sodium bicarbonate must be administered slowly intravenously with a solution of 4.2% to 8 mEq / kg / day.

Promethazine hydrochloride 100mg/4ml

Solution for injection

Promethazine Hydrochloride Injection is indicated for the following conditions:
1. Amelioration of allergic reactions to blood or plasma.
2. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute
symptoms have been controlled.
3. For other uncomplicated allergic conditions of the immediate type when oral therapy is
impossible or contraindicated.
4. For sedation and relief of apprehension and to produce light sleep from which the patient can be
easily aroused.
5. Active treatment of motion sickness.
6. Prevention and control of nausea and vomiting associated with certain types of anaesthesia and
surgery.
7. As an adjunct to analgesics for the control of postoperative pain.
8. Preoperative, postoperative, and obstetric (during labour) sedation.
9. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery,
and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an
adjunct to anaesthesia and analgesia

Route of administration: Intramuscular or intravenous (after dilution)
The usual dose is 25 - 50 mg by deep intramuscular injection, or, in emergency, by slow intravenous injection after dilution of the 2.5% solution to 10 times its volume with water for injections immediately before use.
Maximum parenteral dose 100 mg.
Elderly:No specific dosage recommendations.
Children:6.25 - 12.5 mg for children from 5 - 10 years by deep intramuscular injection. Not for use in children under 2 years of age